Atlanta, GA (November 9, 2013)A variety of recent studies highlight new and innovative research efforts that could help improve individuals' kidney health. Below are the findings of some of these studies, which are being presented at ASN Kidney Week 2013 November 5-10 at the Georgia World Congress Center in Atlanta, GA.
In one study,* Linda Fried, MD, FASN (VA Pittsburgh Healthcare System) and her colleagues examined the effects of combination therapy with two types of blood pressurelowering drugs: angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARB). The combination is known to decrease protein excretion in the urine, which is a marker of kidney dysfunction, but its safety and impact on progression of kidney disease is uncertain. In this latest study, 1148 patients with type 2 diabetes who had moderately decreased kidney function were treated with the ARB losartan and then randomized to receive the ACE inhibitor lisinopril or placebo.
*Additional data from this study are available in the following Late-Breaking Posters: Risk and Severity of Hyperkalemia with Combined Angiotensin Antagonism in Diabetic Nephropathy The VA-NEPHROND Study (SA-PO1089); and Acute Kidney Injury (AKI) Associated with Combined Angiotensin Antagonism in Patients with Diabetic Nephropathy A Secondary Analysis of the VA NEPHRON-D Study (SA-PO1096).
Another team led by Rajiv Agarwal, MD, MBBS, FASN (VA Medical Center in Indianapolis) conducted a clinical trial to assess the safety and efficacy of an ACE inhibitorbased antihypertensive treatment compared with a β-blocker-based antihypertensive treatment. Two hundred patients on hemodialysis who had hypertension and thickened heart muscles were randomized to the ACE inhibitor lisinopril or the β-blocker atenolol, each administered three times weekly after dialysis.
"Contrary to the original hypothesis, the trial found that among kidney dialysis patients with hypertension and thickening of heart muscles, atenolol-based antihypertensive therapy may be superior to lisinopril-based therapy in preventing cardiovascular disease such as heart failure and heart attacks as well as all-cause hospitalizations," said Dr. Agarwal.
Afshin Parsa, MD, FASN (University of Maryland School of Medicine) and his colleagues designed a study to investigate why African Americans are at increased risk for kidney failure, or end stage renal disease (ESRD), compared with European Americans. They focused on variants of the apolipoprotein L1 (APOL1) gene that have been associated with the development of kidney diseases in African Americans. The APOL1 gene creates a protein that is a component of HDL cholesterol. The researchers examined the effects of APOL1 variants on chronic kidney disease (CKD) progression in the African American Study of Kidney Disease and Hypertension (AASK) and the Chronic Renal Insufficiency Cohort Study (CRIC), which together enrolled more than 3600 patients.
The findings provide direct evidence that African Americans with established CKD have a faster kidney function decline and increased rates of kidney failure compared with whites, and that APOL1 risk variants increase CKD progression in African Americans. "The next step of our research will be directed towards delineating which pathways may relate to the APOL1-genotype mediated increase in CKD progression, with the goal of identifying potential targets for treatment," said Dr. Parsa
Finally, Amit Garg, MD, PhD (London Health Sciences Centre, in Ontario) and his team designed a study to see if interventions to reduce the risk acute kidney injury (AKI) in hospitalized patients might preserve long-term kidney function. AKI, an abrupt decline in kidney function, is an increasingly prevalent and potentially serious condition following heart surgery; it occurs because the kidneys are deprived of normal blood flow during the procedure. Within the CORONARY trial, investigators assessed kidney function in 2932 patients from 63 sites in 16 countries who were randomly assigned to coronary-artery bypass grafting (CABG) either with a beating-heart technique (off-pump) or with cardiopulmonary bypass (on-pump).
"The findings emphasize that an intervention that reduces the risk of mild AKI may not necessarily improve long-term kidney function," the researchers concluded.
Combined Angiotensin Inhibition for Treatment of Diabetic Nephropathy: VA Nephron D (Abstract 5780)
Disclosures: Linda F. Fried receives research funding from Reata (site investigator) and Merck (drug donation to Veterans Affairs for study). Nicholas Emanuele receives honoraria from Merck. Paul M. Palevsky is a consultant for Sanofi-Aventis, Cytopherx, Complexa; and receives research funding from Spectral Diagnostics, Inc. Stephen L. Seliger receives research funding from Roche Diagnostics Corporation, and Amgen, Inc. Peter Peduzzi receives honoraria from St. Jude Medical. The authors report receiving support from Veterans Affairs and Merck (study drug donation).
Hypertension in Hemodialysis Patients Treated with Atenolol or Lisinopril (HDPAL): A Randomized Controlled Trial (Abstract 5826)
Disclosures: Rajiv Agarwal is a consultant for and receives honoraria from Abbvie, Amgen, Ardelyx, Bayer, Boehringer Ingelheim, Celgene, Daiichi Sankyo, Reata, Relypsa, Roche, Sandoz, Sigma Tau, Takeda, ZS Pharma; and receives research funding from NIH, VA, Daiichi Sankyo.
APOL1 Risk Variants, Race, and Progression of Chronic Kidney Disease (Abstract 5828)
Disclosures: The authors report receiving research support from the NIDDK.
Acute Kidney Injury from Off-Pump or On-Pump Coronary Bypass Grafting and Kidney Function One Year Later (Abstract 5812)
Disclosures: Amit X. Garg receives research funding from Astellas, Roche, Fresenius, Ortho-Biotech, Pfizer Canada. Salim Yusuf receives research funding and honoraria from Boehringer Ingelheim. Steven G. Coca is a consultant for Aptalis Pharma. Michael Walsh receives research funding from Pfizer, Gambro. Richard J Cook is a consultant for Novartis, Bayer.
|Contact: Kurtis Pivert|
American Society of Nephrology